FDA clears at-home subcutaneous induction for Skyrizi in Crohn’s disease
Federal prosecutors charge 15 in a Los Angeles health care fraud takedown, the FDA approves bepirovirsen (Hibsago) for chronic hepatitis B, and Skyrizi gains at-home subcutaneous induction for Crohn’s disease.
FDA approves Hibsago, the first antisense drug for chronic hepatitis B
The FDA approves Hibsago, the first antisense drug for chronic hepatitis B, the Philips Lumify ultrasound correction becomes a Class I recall after four deaths, and a Maryland lab owner is convicted of Medicare fraud.
HealthSplash owner sentenced to 19 years for $1 billion Medicare brace fraud
The HealthSplash owner gets 19 years for a $1 billion Medicare brace fraud, the FDA flags an Edwards mitral valve delivery system after a death, and Anktiva’s bladder cancer indication expands.